Cargando…

New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown

The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunlap, Denise, Santos, Roberto S., McManus, David D., Buchholz, Bryan O., Hafer, Nathaniel S., Picard, MaryAnn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372191/
https://www.ncbi.nlm.nih.gov/pubmed/34413924
http://dx.doi.org/10.46697/001c.17692
_version_ 1783739765782216704
author Dunlap, Denise
Santos, Roberto S.
McManus, David D.
Buchholz, Bryan O.
Hafer, Nathaniel S.
Picard, MaryAnn
author_facet Dunlap, Denise
Santos, Roberto S.
McManus, David D.
Buchholz, Bryan O.
Hafer, Nathaniel S.
Picard, MaryAnn
author_sort Dunlap, Denise
collection PubMed
description The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities
format Online
Article
Text
id pubmed-8372191
institution National Center for Biotechnology Information
language English
publishDate 2020
record_format MEDLINE/PubMed
spelling pubmed-83721912021-08-18 New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown Dunlap, Denise Santos, Roberto S. McManus, David D. Buchholz, Bryan O. Hafer, Nathaniel S. Picard, MaryAnn AIB Insights Article The 2020s began with a rare coronavirus (COVID-19) disaster, which led to a pandemic-induced recession and Great Lockdown. In response, there has been a worldwide mobilization of resources to detect, treat, and cure the virus. Some policymakers are advocating for the repatriation of globally distributed healthcare know-how. Without a cure for COVID-19, the ambiguity concerning how coronavirus-related policies will impact international business remains unclear. Through a multi-method approach, our study sheds light on two key healthcare industry trends: decentralization and deglobalization of clinical trials. We offer actionable strategies to not only mitigate these challenges, but also to take advantage of their new opportunities 2020-11-03 /pmc/articles/PMC8372191/ /pubmed/34413924 http://dx.doi.org/10.46697/001c.17692 Text en https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY-4.0). View this license’s legal deed at http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) and legal code at http://creativecommons.org/licenses/by/4.0/legalcode (https://creativecommons.org/licenses/by/4.0/) for more information.
spellingShingle Article
Dunlap, Denise
Santos, Roberto S.
McManus, David D.
Buchholz, Bryan O.
Hafer, Nathaniel S.
Picard, MaryAnn
New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title_full New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title_fullStr New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title_full_unstemmed New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title_short New Opportunities and Cautionary Insights about Decentralizing and Deglobalizing Clinical Trials During the Great Lockdown
title_sort new opportunities and cautionary insights about decentralizing and deglobalizing clinical trials during the great lockdown
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372191/
https://www.ncbi.nlm.nih.gov/pubmed/34413924
http://dx.doi.org/10.46697/001c.17692
work_keys_str_mv AT dunlapdenise newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown
AT santosrobertos newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown
AT mcmanusdavidd newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown
AT buchholzbryano newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown
AT hafernathaniels newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown
AT picardmaryann newopportunitiesandcautionaryinsightsaboutdecentralizinganddeglobalizingclinicaltrialsduringthegreatlockdown